Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.11	$3.76	$2.12 ▼ $5.80	$409.85M	1.99	1.52 million shs	1.70 million shs
CYDY CytoDyn	$0.28 +2.4%	$0.30	$0.10 ▼ $0.49	$344.86M	1.23	2.77 million shs	2.55 million shs
IPHYF Innate Pharma	$2.06	$1.56	$1.31 ▼ $2.06	$172.65M	0.47	15 shs	N/A
RIGL Rigel Pharmaceuticals	$39.51 +4.3%	$21.80	$11.95 ▼ $39.68	$708.81M	1.21	278,214 shs	758,445 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+2.49%	+4.58%	+2.24%	+72.69%	+6.48%
CYDY CytoDyn	+3.31%	+2.52%	-13.16%	-31.08%	+105.82%
IPHYF Innate Pharma	0.00%	+57.21%	+57.21%	+42.03%	-1.93%
RIGL Rigel Pharmaceuticals	+3.58%	+24.47%	+100.48%	+91.07%	+216.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	2.0995 of 5 stars	3.5	3.0	3.1	0.0	0.0
CYDY CytoDyn	0.3257 of 5 stars	0.0	2.0	1.1	0.0	1.3
IPHYF Innate Pharma	0.6661 of 5 stars	0.0	3.0	2.6	1.7	0.0
RIGL Rigel Pharmaceuticals	1.8668 of 5 stars	1.2	1.0	3.2	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	146.78% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
IPHYF Innate Pharma	0.00	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-3.32% Downside

Current Analyst Ratings Breakdown

Latest IPHYF, AQST, RIGL, and CYDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	7.12	N/A	N/A	($0.73) per share	-5.63
CYDY CytoDyn	N/A	N/A	$0.00 per share	77.91	($0.08) per share	N/A
IPHYF Innate Pharma	$21.77M	7.93	N/A	N/A	$0.11 per share	18.72
RIGL Rigel Pharmaceuticals	$179.28M	3.95	$1.17 per share	33.91	$4.57 per share	8.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	11/3/2025 (Estimated)
CYDY CytoDyn	$3.74M	$0.01	27.53	∞	N/A	N/A	N/A	-4.40%	10/13/2025 (Estimated)
IPHYF Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.30	37.63	N/A	36.51%	438.89%	57.03%	N/A

Latest IPHYF, AQST, RIGL, and CYDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million
7/25/2025	Q4 2025	CYDY CytoDyn	N/A	-$0.01	N/A	-$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	3.53	4.48
CYDY CytoDyn	N/A	0.25	0.25
IPHYF Innate Pharma	N/A	2.60	2.60
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CYDY CytoDyn	5.06%
IPHYF Innate Pharma	N/A
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
CYDY CytoDyn	0.54%
IPHYF Innate Pharma	31.89%
RIGL Rigel Pharmaceuticals	9.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.40 million	Optionable
CYDY CytoDyn	20	1.25 billion	1.25 billion	Not Optionable
IPHYF Innate Pharma	179	83.83 million	57.10 million	Not Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable

IPHYF, AQST, RIGL, and CYDY Headlines

Recent News About These Companies

Overlooked Stock: RIGL Nearly Doubles Stock in August

1 hour ago | youtube.comY

Rigel Pharmaceuticals (NASDAQ:RIGL) Sets New 12-Month High - Time to Buy?

August 14 at 5:29 AM | marketbeat.com

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

August 13 at 12:38 AM | seekingalpha.com

Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are Of Questionable Quality

August 13 at 11:05 AM | finance.yahoo.com

H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT

August 12 at 8:01 PM | finance.yahoo.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Sees Unusually-High Trading Volume - Time to Buy?

August 10, 2025 | marketbeat.com

RIGL FY2025 EPS Forecast Increased by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Estimate for RIGL Earnings

August 9, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for RIGL Earnings

August 9, 2025 | americanbankingnews.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Reaches New 1-Year High on Analyst Upgrade

August 9, 2025 | americanbankingnews.com

Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?

August 8, 2025 | zacks.com

Best Momentum Stock to Buy for August 8th

August 8, 2025 | zacks.com

Results: Rigel Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

August 8, 2025 | finance.yahoo.com

5 Best Stocks With Relative Price Strength to Buy Right Now

August 8, 2025 | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Hits New 1-Year High Following Analyst Upgrade

August 8, 2025 | marketbeat.com

New Strong Buy Stocks for August 8th

August 8, 2025 | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

August 8, 2025 | americanbankingnews.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2025 Earnings Call Transcript

August 7, 2025 | msn.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

August 7, 2025 | marketbeat.com

Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?

August 7, 2025 | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up After Strong Earnings

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHYF, AQST, RIGL, and CYDY Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.11 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$4.13 +0.02 (+0.49%)

As of 06:35 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

CytoDyn OTCMKTS:CYDY

$0.28 +0.01 (+2.38%)

As of 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Innate Pharma OTCMKTS:IPHYF

$2.06 0.00 (0.00%)

As of 08/14/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Rigel Pharmaceuticals NASDAQ:RIGL

$39.51 +1.62 (+4.28%)

Closing price 04:00 PM Eastern

Extended Trading

$39.56 +0.05 (+0.13%)

As of 06:31 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time